Locations:
Search IconSearch
February 18, 2021/Cancer

Debunking Vaccine Myths for Your Patients

This op-ed offers a Cleveland Clinic expert's view

CC_HE_1250234582_VaccineMyths-745×490

Most physicians and medical professionals understand that the COVID-19 vaccines, especially the mRNA vaccines, are safe, effective and the best way out of this pandemic. The general public, however, is inundated with misinformation and may lack the scientific literacy necessary to dispel circulating myths. Many physicians and scientists are speaking out, offering their knowledge and perspective to a public that is both ready to end the pandemic and confused about vaccine safety and efficacy.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Suneel Kamath, MD, staff in the Department of Hematology and Medical Oncology at Cleveland Clinic Cancer Center, offers his expertise to the public in a recent article in U.S. News & World ReportDr. Kamath places the vaccines in the context of other drug studies for patients:

The concerns about theoretical long-term side effects of the COVID-19 vaccine are valid, but it’s important to contextualize them. The Pfizer vaccine has been studied in nearly 44,000 people, and the Moderna vaccine in 30,000 people, without any meaningful side effects or concerns for long-term issues. In comparison, most studies of the newest immunotherapy and personalized cancer drugs have less than 2,000 patients with minimal long-term safety data. Many people take supplements like cannabis oil or mushroom extracts without any evidence that these are safe long term. With vaccine studies this large and ongoing, there is no reason to scrutinize them any more than a new cancer drug or supplement.

Read the full article here, and consider sharing with patients who are hesitant to get vaccinated.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad